Amundi Increases Stake in Eli Lilly and Company (LLY) by 18367.0%
Amundi, a registered investment adviser, increased its position in Eli Lilly and Company (NYSE:LLY) by 18367.0% during Q2 2026, according to its most recent 13F filing with the…
Eli Lilly and Company (NYSE:LLY) · position increase
Institution
Amundi
Institution type
investment_adviser
Reporting period
Q2 2026
Shares
4,423,772
Position value
$5.3B
Position change
18,367.01%
At a glance
Key takeaways
01Amundi increased its Eli Lilly stake by 18,367% in Q2 2026, purchasing 4.4 million additional shares to reach a total position of 4.4 million shares valued at approximately $5.3 billion.
02Eli Lilly stock trades at $1,205 per share with a market capitalization of $906.5 billion, and Amundi's position represents one of the more significant institutional holdings in the company.
03The 13F filing reflects holdings as of the end of Q2 2026 and was filed up to 45 days later, meaning the actual position may have changed since the reported date.
Filing Details
Amundi, a registered investment adviser, increased its position in Eli Lilly and Company (NYSE:LLY) by 18367.0% during Q2 2026, according to its most recent 13F filing with the Securities and Exchange Commission.
The firm purchased an additional 4,399,817 shares of the Healthcare company, bringing its total holdings to 4,423,772 shares valued at approximately $5.3B as of the filing date.
Market Context
Eli Lilly and Company's stock currently trades at $1205.00 with a market capitalization of $906.5B.
An increase in an existing position suggests Amundi has growing conviction in Eli Lilly and Company's trajectory. Institutional investors typically add to positions when they believe the stock still has upside relative to their price target, or when the company's fundamentals have improved since their initial purchase.
Healthcare stocks have attracted institutional attention as an aging population drives long-term demand. Eli Lilly and Company operates in a sector where regulatory developments and pipeline progress can significantly impact institutional positioning.
The size of this position — $5.31 billion — places it among the more significant institutional holdings in Eli Lilly and Company. Large positions like this can influence trading dynamics and are closely watched by market participants tracking smart money flows.
Investors should note that 13F filings reflect holdings as of the end of the reporting quarter and are filed up to 45 days later. The position may have changed since the filing date. 13F data is most useful when analyzed alongside other signals such as insider transactions, analyst ratings, and fundamental trends.
A 13F filing is a quarterly SEC report required for institutional managers with over $100 million in assets. It discloses equity holdings, providing transparency into how firms like Amundi position their portfolios.